In this research, the tryptoline core compound previously reported as BACE1 inhibitor was modified in silico to possess multi-modes of action for the treatment of Alzheimer’s disease i.e., anti-amyloid aggregation, metal chelating and radical scavenging action. Here, BACE1 is linked to Alzheimer disease.